Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma
Tóm tắt
Bone disease is a major symptom of multiple myeloma, which results from excessive osteoclast activation and impaired osteoblast function. Novel antimyeloma agents, such as immunomodulatory drugs and bortezomib, alter bone metabolism in patients with this disease. However, recent studies have shown that bortezomib affects bone formation and healing, but immunomodulatory drugs do not. We report a case of refractory multiple myeloma that was treated with lenalidomide combined with dexamethasone (RD regimen). As a result, the patient’s myeloma protein expression was markedly reduced, and her hematological profile was improved. However, the treatment also induced tetany by reducing her serum calcium and magnesium levels and elevating her alkaline phosphatase levels. In addition, conventional radiography and computed tomography detected osteosclerosis. These findings suggest that the RD regimen affects bone formation, possibly by activating osteoblasts. This is to our knowledge the first report to suggest that lenalidomide, an immunomodulatory drug, affects osteogenesis, at least in a certain subpopulation of patients with multiple myeloma.
Tài liệu tham khảo
Terpos E, Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol. 2005;16:1223–31.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia. 2007;21:1875–84.
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burn MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71–3.
Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Migkou M, Tsionos K, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol. 2010;21:1561–2.
De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestis F. Constitutive down regulation of osterix in osteoblasts from myeloma patients: in vitro effect of bortezomib and lenalidomide. Leuk Res. 2010;34:243–9.
Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogues but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008;33:129–36.
Terpos E. Advances in imaging and management of myeloma bone disease. J Clin Oncol. 2011;29:1907–15.
Christoulas D, Dimopoulos M, Katodritou E, Kyrtsonis M, Parharidou A, Delipasi S, et al. The combination of lenalidomide and dexamethasone reduced bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation. Haematologica. 2010;95(s2):397.
Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescia R, et al. International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010;24:1700–12.
Dimopoulos MA, Palumbo A, Attal M, Baksac M, Davies EF, Delforge M, European Myeloma Network, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749–60.
Celgene Corpotation. Revmid Full prescribing information. http://www.revmid.com/docs/Revmid-Full-PI.pdf. Accessed Feb 2012.